PMID- 32098708
OWN - NLM
STAT- MEDLINE
DCOM- 20210507
LR  - 20210507
IS  - 1464-3391 (Electronic)
IS  - 0968-0896 (Linking)
VI  - 28
IP  - 7
DP  - 2020 Apr 1
TI  - Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers.
PG  - 115379
LID - S0968-0896(20)30175-9 [pii]
LID - 10.1016/j.bmc.2020.115379 [doi]
AB  - Enhancer of Zeste Homolog 2 (EZH2) is highly expressed in kinds of malignant 
      tumors and related to tumor occurrence, development, and prognosis. EZH2 is the 
      catalytic subunit of the polycomb repressive complex 2 (PRC2), which promotes 
      cell proliferation, migration, and invasion by epigenetic regulation of 
      anti-tumor gene. It can activate numerous tumor-associated signaling pathways and 
      interfere with DNA damage repair. In recent years, large amounts of studies have 
      shown that EZH2 is closely related to gynecologic-related malignancies and can be 
      used as a potential target gene for the treatment of gynecological-related 
      malignancies. This review summarizes the oncogenic function of EZH2 and 
      introduces the recent advances in the development of EZH2 inhibitors. On this 
      basis, future research prospect of EZH2 is proposed.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Wan, Zhong
AU  - Wan Z
AD  - Urologic Medical Center, Shanghai General Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai, China.
FAU - Jiang, Huabo
AU  - Jiang H
AD  - Clinical and Translational Research Center, Shanghai First Maternity and Infant 
      Hospital, Tongji University School of Medicine, Shanghai, China.
FAU - Li, Li
AU  - Li L
AD  - Assisted Reproduction Technology Center, Shuguang Hospital Affiliated to Shanghai 
      University of Traditional Chinese Medicine, Shanghai, China.
FAU - Zhu, Shuhui
AU  - Zhu S
AD  - Department of Food and Drug Engineering, Shandong Vocational Animal Science and 
      Veterinary College, Weifang, Shandong, China.
FAU - Hou, Jingjing
AU  - Hou J
AD  - Department of Gastrointestinal Surgery, Institute of Gastrointestinal Oncology, 
      Zhongshan Hospital of Xiamen University, Xiamen, Fujian, China. Electronic 
      address: jjhou@xmu.edu.cn.
FAU - Yu, Yongsheng
AU  - Yu Y
AD  - Clinical and Translational Research Center, Shanghai First Maternity and Infant 
      Hospital, Tongji University School of Medicine, Shanghai, China. Electronic 
      address: yongshengyu@tongji.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200217
PL  - England
TA  - Bioorg Med Chem
JT  - Bioorganic & medicinal chemistry
JID - 9413298
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Enhancer of Zeste Homolog 2 Protein/antagonists & inhibitors/genetics/*metabolism
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/*drug effects
MH  - Genital Neoplasms, Female/*drug therapy/*enzymology
MH  - Humans
OTO - NOTNLM
OT  - Enhancer of zeste homolog 2 (EZH2)
OT  - Gynecologic-relate malignancies
OT  - Polycomb group
OT  - Targeted inhibitors
COIS- Declaration of Competing Interest The authors declared that there is no conflict 
      of interest.
EDAT- 2020/02/27 06:00
MHDA- 2021/05/08 06:00
CRDT- 2020/02/27 06:00
PHST- 2019/11/20 00:00 [received]
PHST- 2020/02/10 00:00 [revised]
PHST- 2020/02/12 00:00 [accepted]
PHST- 2020/02/27 06:00 [pubmed]
PHST- 2021/05/08 06:00 [medline]
PHST- 2020/02/27 06:00 [entrez]
AID - S0968-0896(20)30175-9 [pii]
AID - 10.1016/j.bmc.2020.115379 [doi]
PST - ppublish
SO  - Bioorg Med Chem. 2020 Apr 1;28(7):115379. doi: 10.1016/j.bmc.2020.115379. Epub 
      2020 Feb 17.